Pseudomonas aeruginosa exoenzyme S is a mitogen but not a superantigen for human T lymphocytes.
Virtually all cystic fibrosis (CF) patients become infected with Pseudomonas aeruginosa, and once the infection is established, the organism is rarely cleared. One of the P. aeruginosa virulence factors, exoenzyme S, has been shown to correlate with increased morbidity and mortality both in rat models of chronic pulmonary inflammation and in human CF patients. It has previously been shown that exoenzyme S is a potent stimulus for the proliferation of T cells in greater than 95% of adults, which could contribute to the pathogenesis of CF. The goal of this study was to determine the mechanism of T-cell stimulation by exoenzyme S in an effort to shed light on the immune response and contribute to understanding its role in P. aeruginosa pathogenesis. The current studies demonstrate that exoenzyme S stimulates naive T cells, since fetal blood lymphocytes proliferated and adult lymphocytes that expressed CD45RA proliferated. The percentage of T cells activated by exoenzyme S after a 4-h culture (as measured by CD69 surface expression) was intermediate in magnitude compared to levels induced by a panel of superantigens and mitogens. To determine the mechanism of activation, the requirement for accessory cells was investigated. The proliferative response to exoenzyme S was dependent on the presence of accessory cells but was not blocked by an anti-DR antibody. Exoenzyme S activated both CD4(+) and CD8(+) T cells, but CD4(+) T cells were preferentially activated. The Vbeta repertoire of donor T cells showed no preferential activation or preferential expansion after stimulation by exoenzyme S, suggesting that it is not a superantigen. Taken together, our data suggest that exoenzyme S is a T-cell mitogen but not a superantigen. Activation of a large percentage of T lymphocytes by exoenzyme S may produce a lymphocyte-mediated inflammatory response that should be considered in the pathogenesis of CF.
Bruno
T F
TF
Department of Microbiology and Infectious Diseases, University of Calgary, Calgary, Alberta, Canada.
Buser
D E
DE
Syme
R M
RM
Woods
D E
DE
Mody
C H
CH
D036002:ADP Ribose Transferases; D000328:Adult; D001427:Bacterial Toxins; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000276:immunology; D003550:Cystic Fibrosis / Q000276:immunology / Q000628:therapy; D006801:Humans; D007156:Immunologic Memory; D008213:Lymphocyte Activation / Q000187:drug effects*; D008285:Major Histocompatibility Complex / Q000502:physiology; D008934:Mitogens / Q000494:pharmacology*; D011065:Poly(ADP-ribose) Polymerases / Q000494:pharmacology*; D011550:Pseudomonas aeruginosa / Q000472:pathogenicity*; D018089:Superantigens / Q000494:pharmacology*; D013601:T-Lymphocytes / Q000276:immunology*
D001427:Bacterial Toxins; D008934:Mitogens; D018089:Superantigens; D036002:ADP Ribose Transferases; D011065:Poly(ADP-ribose) Polymerases; C444820:exoenzyme S